Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240039/S003

Charger SetPoint System

SetPoint Medical · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP240039/S003

What did the FDA decide?

The FDA database entry for supplement S003 to PMA P240039 records an OK30 decision dated 2026-10-16. The statement describes approval for manufacturing changes to the Charger Litz Wire Cleaning method and the printed circuit board assembly (PCBA). The supplement type is a 30-Day Notice, and the stated reason is a process change involving manufacturer, sterilizer, packager, or supplier.

The device category is a vagus nerve stimulator for rheumatoid arthritis, with product code SFJ and applicant SetPoint Medical. The entry does not state what the specific cleaning method change or PCBA change involves, nor does it provide safety or effectiveness data. A supplement is not a new approval of the whole system, and the statement's reported purpose is distinct from independent proof of clinical benefit.

FDA approval order statement

Approval for manufacturing changes to Charger Litz Wire Cleaning method and the printed circuit board assembly (PCBA).
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Oct 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240039/S003
Regulatory pathway
PMA supplement
Product code
SFJ
Decision code
OK30
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Vagus nerve stimulator for rheumatoid arthritis.

Product code
SFJ
FDA device class
3

For the original device and its historical approval scope, see PMA P240039. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240039/S003 received

    Application receipt date recorded by FDA.

  2. P240039/S003 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240039. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240039

Product / regulatory recordCompanyPathwayDecision dateSource
SetPoint MedicalPMA approvalJul 30, 2025FDA
SetPoint SystemP240039/S004
SetPoint MedicalPMA supplementOct 29, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

SetPoint Medical

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
25101 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records